{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T22:49:10Z","timestamp":1782254950920,"version":"3.54.5"},"update-to":[{"DOI":"10.1002\/14651858.cd012877","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T00:00:00Z","timestamp":1589587200000}}],"reference-count":68,"publisher":"Wiley","issue":"5","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd012877.pub2","type":"journal-article","created":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T08:27:46Z","timestamp":1589617666000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Adalimumab for maintenance of remission in Crohn's disease"],"prefix":"10.1002","volume":"2020","author":[{"given":"Cassandra M","family":"Townsend","sequence":"additional","affiliation":[{"name":"Department of Medicine; University of Western Ontario; London Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tran M","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Robarts Clinical Trials; London Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Cepek","sequence":"additional","affiliation":[{"name":"Schulich School of Medicine & Dentistry; University of Western Ontario; London Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Abbass","sequence":"additional","affiliation":[{"name":"Schulich School of Medicine & Dentistry; University of Western Ontario; London Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire E","family":"Parker","sequence":"additional","affiliation":[{"name":"Robarts Clinical Trials; London Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John K","family":"MacDonald","sequence":"additional","affiliation":[{"name":"Department of Medicine; University of Western Ontario; London Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reena","family":"Khanna","sequence":"additional","affiliation":[{"name":"Department of Medicine; University of Western Ontario; London Canada"},{"name":"Robarts Clinical Trials; London Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vipul","family":"Jairath","sequence":"additional","affiliation":[{"name":"Department of Medicine; University of Western Ontario; London Canada"},{"name":"Robarts Clinical Trials; London Canada"},{"name":"Department of Epidemiology and Biostatistics; University of Western Ontario; London Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian G","family":"Feagan","sequence":"additional","affiliation":[{"name":"Department of Medicine; University of Western Ontario; London Canada"},{"name":"Robarts Clinical Trials; London Canada"},{"name":"Department of Epidemiology and Biostatistics; University of Western Ontario; London Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,5,16]]},"reference":[{"issue":"1","key":"10.1002\/14651858.CD012877.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","article-title":"Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial","volume":"132","author":"Colombel","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012877.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"A229","DOI":"10.1136\/gutjnl-2012-302514c.109","article-title":"Efficacy and safety of adalimumab in moderate compared with severe Crohn's disease: Pooled data from the charm and extend trials","volume":"61","author":"Colombel","year":"2012","journal-title":"Gut"},{"issue":"5","key":"10.1002\/14651858.CD012877.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1038\/ajg.2009.59","article-title":"Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: Results from the CHARM trial","volume":"104","author":"Colombel","year":"2009","journal-title":"American Journal of Gastroenterology"},{"issue":"7","key":"10.1002\/14651858.CD012877.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1136\/gut.2008.159251","article-title":"Adalimumab for the treatment of fistulas in patients with Crohn's disease","volume":"58","author":"Colombel","year":"2009","journal-title":"Gut"},{"issue":"7","key":"10.1002\/14651858.CD012877.pub2-BIB0005|cit5","first-page":"486","article-title":"The CHARM trial of adalimumab in Crohn's disease","volume":"2","author":"Colombel","year":"2006","journal-title":"Gastroenterology and Hepatology"},{"issue":"5","key":"10.1002\/14651858.CD012877.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1053\/j.gastro.2008.07.069","article-title":"Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study","volume":"135","author":"Feagan","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012877.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"S449","DOI":"10.14309\/00000434-201110002-01196","article-title":"Adalimumab maintenance therapy improves patient-reported outcomes in patients with moderate Crohn's disease: Subanalysis of CHARM","volume":"106","author":"Loftus","year":"2011","journal-title":"American Journal of Gastroenterology"},{"issue":"12","key":"10.1002\/14651858.CD012877.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1111\/j.1572-0241.2008.02175.x","article-title":"Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: Patient-reported outcomes of the CHARM trial","volume":"103","author":"Loftus","year":"2008","journal-title":"American Journal of Gastroenterology"},{"issue":"5","key":"10.1002\/14651858.CD012877.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1002\/ibd.21836","article-title":"Effect of adalimumab on clinical laboratory parameters in patients with Crohn's disease: results from the CHARM trial","volume":"18","author":"Rubin","year":"2012","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1002\/14651858.CD012877.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"S106","DOI":"10.1016\/S1873-9946(12)60263-3","article-title":"Subgroup analysis of the placebo-controlled CHARM trial: Increased remission rates for adalimumab-treated patients with early Crohn's disease","volume":"6","author":"Schreiber","year":"2012","journal-title":"Journal of Crohn's and Colitis"},{"issue":"1","key":"10.1002\/14651858.CD012877.pub2-BIB0011|cit11","first-page":"S68","article-title":"Effect of concomitant immunomodulator use on the efficacy of adalimumab in Crohn's disease patients stratified by prior anti-TNF use","volume":"5","author":"Vermeire","year":"2011","journal-title":"Journal of Crohn's and Colitis"},{"issue":"8","key":"10.1002\/14651858.CD012877.pub2-BIB0012|cit12","first-page":"1291","article-title":"Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial","volume":"50","author":"Wasvary","year":"2007","journal-title":"Diseases of the Colon and Rectum"},{"issue":"1","key":"10.1002\/14651858.CD012877.pub2-BIB0013|cit13","first-page":"S41","article-title":"Economic impact of deep remission in adalimumab-treated patients with Crohn's disease: Results from EXTEND","volume":"5","author":"Colombel","year":"2011","journal-title":"Journal of Crohn's and Colitis"},{"key":"10.1002\/14651858.CD012877.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1093\/ibd\/17.supplement1.S44","article-title":"Effect of disease duration on 'deep remission': Results from the EXTEND trial","volume":"17","author":"Colombel","year":"2011","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1002\/14651858.CD012877.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"S434","DOI":"10.14309\/00000434-201010001-01190","article-title":"Achievement of early deep remission predicts better long-term outcomes for adalimumab-treated patients with Crohn's disease: Data from extend","volume":"105","author":"Colombel","year":"2010","journal-title":"American Journal of Gastroenterology"},{"issue":"5","key":"10.1002\/14651858.CD012877.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1093\/ibd\/izx082","article-title":"Performance of Crohn's disease clinical trial endpoints based upon different cutoffs for patient reported outcomes or endoscopic activity: Analysis of EXTEND data","volume":"24","author":"Feagan","year":"2018","journal-title":"Inflammatory Bowel Diseases"},{"issue":"4","key":"10.1002\/14651858.CD012877.pub2-BIB0017|cit17","first-page":"425","article-title":"Characterisation of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn\u2019s disease: Results from the EXTEND Trial","volume":"11","author":"Reinisch","year":"2017","journal-title":"Journal of Crohn's & Colitis"},{"key":"10.1002\/14651858.CD012877.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"S475","DOI":"10.14309\/00000434-201410002-01611","article-title":"Characterization of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn's disease from extend","volume":"109","author":"Reinisch","year":"2014","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD012877.pub2-BIB0019|cit19","first-page":"A537","article-title":"Characterization of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn's disease from extend","volume":"1","author":"Reinisch","year":"2014","journal-title":"United European Gastroenterology Journal"},{"key":"10.1002\/14651858.CD012877.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/S1873-9946(14)60058-1","article-title":"Evaluation of site versus central assessment of endoscopies in Crohn's disease: Comparison using data from EXTEND","volume":"8","author":"Rutgeerts","year":"2014","journal-title":"Journal of Crohn's & Colitis"},{"issue":"5","key":"10.1002\/14651858.CD012877.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1053\/j.gastro.2012.01.035","article-title":"Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial","volume":"142","author":"Rutgeerts","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012877.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"S585","DOI":"10.1016\/S0016-5085(14)62121-1","article-title":"Evaluation of site versus central assessment of endoscopies in Crohn's disease: Comparison using data from extend","volume":"1","author":"Rutgeerts","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012877.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"S442","DOI":"10.14309\/00000434-201010001-01208","article-title":"Achievement of early deep remission is associated with lower rates of weekly dosing for adalimumab-treated patients with Crohn's disease: Data from EXTEND","volume":"105","author":"Sandborn","year":"2010","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD012877.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"S112","DOI":"10.1016\/S1873-9946(12)60277-3","article-title":"Importance of deep remission compared with mucosal healing only: Results from EXTEND","volume":"6","author":"Sandborn","year":"2012","journal-title":"Journal of Crohn's & Colitis"},{"key":"10.1002\/14651858.CD012877.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"S589","DOI":"10.1016\/S0016-5085(14)62134-X","article-title":"Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from extend","volume":"1","author":"Sandborn","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012877.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"A136","DOI":"10.1136\/gut.2011.239301.290","article-title":"Achievement of early deep remission is associated with lower rates of weekly dosing for adalimumab-treated patients with Crohn's disease: Data from extend","volume":"60","author":"Sandborn","year":"2011","journal-title":"Gut"},{"key":"10.1002\/14651858.CD012877.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"S306","DOI":"10.1016\/S1873-9946(14)60692-9","article-title":"Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from EXTEND","volume":"8","author":"Sandborn","year":"2014","journal-title":"Journal of Crohn's & Colitis"},{"key":"10.1002\/14651858.CD012877.pub2-BIB0028|cit28","first-page":"118","article-title":"Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from EXTEND","volume":"29","author":"Sandborn","year":"2014","journal-title":"Journal of Gastroenterology and Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD012877.pub2-BIB0029|cit29","first-page":"S88","article-title":"Impact of induction dosing on maintenance outcome with adalimumab in Crohn's disease","volume":"5","author":"Colombel","year":"2011","journal-title":"Journal of Crohn's & Colitis"},{"issue":"9","key":"10.1002\/14651858.CD012877.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1136\/gut.2006.106781","article-title":"Adalimumab for maintenance treatment of Crohn's disease: Results of the CLASSIC II trial","volume":"56","author":"Sandborn","year":"2007","journal-title":"Gut"},{"key":"10.1002\/14651858.CD012877.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"S94","DOI":"10.1016\/S1590-8658(13)60261-3","article-title":"Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease-a randomized trial","volume":"45","author":"Savarino","year":"2013","journal-title":"Digestive and Liver Disease"},{"key":"10.1002\/14651858.CD012877.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/S0016-5085(13)60072-4","article-title":"Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease-a randomized trial","volume":"1","author":"Savarino","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012877.pub2-BIB0033|cit33","first-page":"A17","article-title":"Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease-a randomized trial","volume":"1","author":"Savarino","year":"2013","journal-title":"United European Gastroenterology Journal"},{"key":"10.1002\/14651858.CD012877.pub2-BIB0034|cit34","first-page":"A458","article-title":"Early initiation of adalimumab significantly diminishes endoscopic post-operative Crohn's disease recurrence, and is superior to immunomodulatory therapy, regardless of risk stratification. A randomized, controlled study","volume":"6","author":"Scapa","year":"2018","journal-title":"United European Gastroenterology Journal"},{"key":"10.1002\/14651858.CD012877.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"S303","DOI":"10.1093\/ecco-jcc\/jju027.565","article-title":"Early initiation of adalimumab significantly diminishes post-operative Crohn's Disease recurrence, and is superior to immunomodulator therapy. Preliminary results from the POPART trial","volume":"9","author":"Scapa","year":"2015","journal-title":"Journal of Crohn's & Colitis"},{"key":"10.1002\/14651858.CD012877.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"S240","DOI":"10.1016\/S0016-5085(15)30790-3","article-title":"Early initiation of adalimumab significantly diminishes post-operative Crohn's disease recurrence, and is superior to immunomodulator therapy. Preliminary results from the POPART trial","volume":"1","author":"Scapa","year":"2015","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD012877.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.crohns.2011.07.013","article-title":"Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease","volume":"6","author":"Watanabe","year":"2012","journal-title":"Journal of Crohn's & Colitis"},{"issue":"9976","key":"10.1002\/14651858.CD012877.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1016\/S0140-6736(14)61908-5","article-title":"Crohn's disease management after intestinal resection: A randomised trial","volume":"385","author":"De Cruz","year":"2014","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD012877.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1136\/gutjnl-2013-304488","article-title":"Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI)","volume":"63","author":"Dewint","year":"2014","journal-title":"Gut"},{"issue":"3","key":"10.1002\/14651858.CD012877.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/MIB.0000000000001021","article-title":"Long-term efficacy and safety of adalimumab in paediatric patients with Crohn\u2019s disease","volume":"23","author":"Faubion","year":"2017","journal-title":"Inflammatory Bowel Diseases"},{"issue":"10006","key":"10.1002\/14651858.CD012877.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/S0140-6736(15)00068-9","article-title":"Early combined immunosuppression for the management of Crohn's disease (REACT): A cluster randomised controlled trial","volume":"386","author":"Khanna","year":"2015","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD012877.pub2-BIB0042|cit42","unstructured":"Safety and efficacy of adalimumab versus ustekinumab for one year (SEAVUE) clinicaltrials.gov\/ct2\/show\/NCT03464136"},{"issue":"6","key":"10.1002\/14651858.CD012877.pub2-BIB0043|cit43","first-page":"153","article-title":"Adalimumab treatment in Crohn's disease: an overview of long-term efficacy and safety in light of the EXTEND trial","volume":"6","author":"Asgharpour","year":"2013","journal-title":"Clinical and Experimental Gastroenterology"},{"issue":"7","key":"10.1002\/14651858.CD012877.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa020888","article-title":"Influence of immunogenicity on the long-term efficacy of infliximab in Crohn\u2019s disease","volume":"348","author":"Baert","year":"2003","journal-title":"New England Journal of Medicine"},{"issue":"9853","key":"10.1002\/14651858.CD012877.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S0140-6736(12)60026-9","article-title":"Crohn's disease","volume":"380","author":"Baumgart","year":"2012","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD012877.pub2-BIB0046|cit46","first-page":"763","article-title":"Adalimumab for the treatment of Crohn's disease","volume":"2","author":"Cassinotti","year":"2008","journal-title":"Biologics"},{"issue":"6","key":"10.1002\/14651858.CD012877.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1053\/j.gastro.2011.01.054","article-title":"The commensal microbiota and enteropathogens in the pathogenesis of inflammatory bowel diseases","volume":"140","author":"Chassaing","year":"2011","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD012877.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1053\/gast.1996.v110.pm8566589","article-title":"Effects of cigarette smoking on the long-term course of Crohn's disease","volume":"110","author":"Cosnes","year":"1996","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD012877.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1136\/gut.53.1.70","article-title":"Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn\u2019s disease","volume":"53","author":"Di Sabatino","year":"2004","journal-title":"Gut"},{"key":"10.1002\/14651858.CD012877.pub2-BIB0050|cit50","volume-title":"Current Diagnosis & Treatment","author":"Doherty","year":"2015"},{"issue":"7109","key":"10.1002\/14651858.CD012877.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD012877.pub2-BIB0052|cit52","unstructured":"HUMIRA: Highlights of prescribing information www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/125057s0110lbl.pdf"},{"issue":"1","key":"10.1002\/14651858.CD012877.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.crohns.2007.06.005","article-title":"Impact of inflammatory bowel disease on quality of life: Results of the European Federation of Crohn\u2019s and Ulcerative Colitis Associations (EFCCA) patient survey","volume":"1","author":"Ghosh","year":"2007","journal-title":"Journal of Crohn's & Colitis"},{"issue":"7650","key":"10.1002\/14651858.CD012877.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"9317","key":"10.1002\/14651858.CD012877.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"issue":"7414","key":"10.1002\/14651858.CD012877.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analysis","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD012877.pub2-BIB0057|cit57","unstructured":"Higgins JP Altman DG Sterne JA Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). The Cochrane Collaboration, 2017 Available from www.training.cochrane.org\/handbook"},{"issue":"7351","key":"10.1002\/14651858.CD012877.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nature10209","article-title":"Genetics and pathogenesis of inflammatory bowel disease","volume":"474","author":"Khor","year":"2011","journal-title":"Nature"},{"key":"10.1002\/14651858.CD012877.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2015.00551","article-title":"Inflammatory bowel disease: genetics, epigenetics and pathogenesis","volume":"6","author":"Loddo","year":"2015","journal-title":"Frontiers in Immunology"},{"issue":"1","key":"10.1002\/14651858.CD012877.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s00281-014-0454-4","article-title":"The gut microbiota and inflammatory bowel disease","volume":"37","author":"Matsuoka","year":"2015","journal-title":"Seminars in Immunopathology"},{"issue":"10","key":"10.1002\/14651858.CD012877.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1097\/MEG.0000000000001538","article-title":"Time to antibody detection and associated factors for presence of anti-drug antibodies in pediatric inflammatory bowel disease patients treated with anti-TNF therapy","volume":"31","author":"Moses","year":"2019","journal-title":"European Journal of Gastroenterology & Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD012877.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1136\/gut.35.3.360","article-title":"Frequency of glucocorticoid resistance and dependency in Crohn's disease","volume":"35","author":"Munkholm","year":"1994","journal-title":"Gut"},{"key":"10.1002\/14651858.CD012877.pub2-BIB0063|cit63","unstructured":"Sch\u00fcnemann HJ Oxman AD Vist GE Higgins JP Deeks JJ Glasziou P on behalf of the Cochrane Applicability and Recommendations Methods Group Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). The Cochrane Collaboration, 2017 Available from www.training.cochrane.org\/handbook"},{"issue":"4","key":"10.1002\/14651858.CD012877.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"394\u2013409","DOI":"10.1111\/apt.14852","article-title":"Systematic review and network meta-analysis: first- and second-line biologic therapies for moderate-severe Crohn\u2019s disease","volume":"48","author":"Singh","year":"2018","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"4","key":"10.1002\/14651858.CD012877.pub2-BIB0065|cit65","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000301","article-title":"Corticosteroids for maintenance of remission in Crohn\u2019s disease","author":"Steinhart","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD012877.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.pharmthera.2007.10.001","article-title":"Tumor necrosis factor antagonist mechanisms of action: a comprehensive review","volume":"117","author":"Tracey","year":"2008","journal-title":"Pharmacology Therapy"},{"issue":"4","key":"10.1002\/14651858.CD012877.pub2-BIB0067|cit67","first-page":"413","article-title":"Is top-down therapy a more effective alternative to conventional step-up therapy for Crohn's disease?","volume":"31","author":"Tsui","year":"2018","journal-title":"Annals of Gastroenterology"},{"issue":"11","key":"10.1002\/14651858.CD012877.pub2-BIB0068|cit68","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012877","article-title":"Adalimumab for maintenance of remission in Crohn's disease (Protocol)","author":"Khanna","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T22:01:09Z","timestamp":1704232869000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD012877.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane IBD Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,5,16]]},"references-count":68,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,5]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd012877.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,16]]}}}